NASDAQ
238.90USD
+4.57 (+1.95%)
We have scored 24 news catalysts on Ascendis Pharma A/S (ASND) over the past 12 months. The biggest single-day move next to one of them came Dec 5, 2025, when ASND closed −1.5%: “Ascendis: Q3 Results Validate The TransCon Platform”. Coverage across the window leans positive (average ticker sentiment +0.46). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
14.9B
P/E
—
EPS
—
Beta
0.37
52W range
188.07-282.15
Day range
236.00–240.21
Open
236.00
Prev close
234.33
Volume
662K
Avg volume
734.8K
Dividend
0.00
IPO
2015-01-28
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Ascendis Pharma A/S — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ASND: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
